Assuring the safety and effectiveness of new drugs: rigorous phase IV trials randomizing general practices to delayed access to new drugs

Original article by: J Adamson, T van Staa, D Torgerson

Reference: Journal of Health Services Research and Policy Jan 2012;17(1):56-59

Source: Journal of Health Services Research and Policy

Keywords: Adverse Effects; Clinical Trials; Doctors-General Practice; New Products; Postmarketing Surveillance; Prescribing; Random Allocation; United Kingdom; Viewpoint;

Date published: 07/02/2012 13:45

Summary
by: Pharm-line

Randomised trials are crucial for establishing the effectiveness of new drugs and procedures.  However, they are less effective at detecting uncommon but clinically significant side effects.  The authors propose a solution.  All UK general practices could be randomized to be allowed to prescribe new licenced drugs earlier or later.  This would produce a large pragmatic cluster trial which could enable rare, but harmful, effects to be demonstrated more quickly than the current usual practice of looking for harmful events in observational datasets.  Given current computerisation of practice records such an approach is feasible and likely to be cost-effective.

About this library entry

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.